Ranran Kong

Dr. Ranran Kong

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2016 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
RKRanran Kong
Ranran Kong
YMYuefeng Ma
Yuefeng Ma
JFJie Feng
Jie Feng
SLShaomin Li
Shaomin Li
WZWei Zhang
Wei Zhang
BZBin Zhou
Bin Zhou
MiR-126 is a key regulator of oncogenic processes. It is functionally linked to cellular proliferation, survival and migration. Vascular endothelial growth factor A (VEGF-A), which is regarded as a tumorgenesis activator, could directly target miR-126 in several tumors. However, the mechanism in esophageal cancer remains unclear. In this study, the expression of miR-126 and VEGF-A were assessed in esophageal cancer tissues and esophageal cancer cell lines. We found that miR-126 has significantly lower expression in esophageal cancer tissues and esophageal cancer cell lines than in healthy tissues, while the expression of VEGF-A is high. Luciferase reporter assays were performed to investigate the relationship between VEGF-A and miR-126. We confirmed that VEGF-A is a target for miR-126. Furthermore, the proliferation of esophageal cancer cells with miR-126 overexpression and miR-126 knockdown was monitored using the MTT assay. The results showed that miR-126 could inhibit esophageal cancer cell proliferation in vitro. The effect of miR-126 was also detected in BALB/c nude mice with transplanted esophageal cancer cells. In vivo study showed that tumor growth was significantly suppressed by miR-126 overexpression. We believe that restoring miR-126 levels may be a promising therapeutic approach in cases of esophageal cancer.

28 January 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JFJie Feng
Jie Feng
LXLiyi Xie
Liyi Xie
XYXiaoyang Yu
Xiaoyang Yu
CLChao Liu
Chao Liu
HDHongjuan Dong
Hongjuan Dong
RKRanran Kong
Ranran Kong

15 December 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
RKRanran Kong
Ranran Kong
APAyushi S. Patel
Ayushi S. Patel
TSTakashi Sato
Takashi Sato
FJFeng Jiang
Feng Jiang
SYSeungyeul Yoo
Seungyeul Yoo
HWHideo Watanabe
Hideo Watanabe
Rationale: The current molecular classification of small cell lung cancer (SCLC) based on expression of four lineage transcription factors still leaves its major subtype SCLC-A as a heterogeneous group, necessitating more precise characterization of lineage subclasses. Objectives: To refine the current SCLC classification with epigenomic profiles and to identify features of the re-defined SCLC subtypes. Methods: We performed unsupervised clustering of epigenomic profiles on 25 SCLC cell lines. Functional significance of NKX2-1 was evaluated by cell growth, apoptosis and xenograft using CRISPR-Cas9-mediated deletion. NKX2-1 specific cistromic profiles were determined by ChIP-seq and its functional transcriptional partners were determined using co-immunoprecipitation followed by mass-spectrometry. Rb1fl/flTrp53fl/fl and Rb1fl/flTrp53fl/flNkx2-1fl/fl mouse models were engineered to explore the function of Nkx2-1 in SCLC tumorigenesis. Epigenomic landscapes of 6 human SCLC specimens and 20 tumors from 2 mouse models were characterized. Measurements and Main Results: We identified an epigenomic subcluster of the major SCLC-A subtype: SCLC-Aα and SCLC-Aσ. SCLC-Aα was characterized by the presence of a super-enhancer at the NKX2-1 locus, which was observed in human SCLC specimens and a murine SCLC model. We found NKX2-1, a dual lung and neural lineage factor, is uniquely relevant in SCLC-Aα. Additionally, we found maintenance of this neural identity in SCLC-Aα is mediated by collaborative transcriptional activity with another neuronal transcriptional factor SOX1. Conclusions: We comprehensively describe additional epigenomic heterogeneity of the major SCLC-A subtype, and define SCLC-Aα subtype by the core regulatory circuitry of NKX2-1 and SOX1 super-enhancers and their functional collaborations to maintain neuronal linage state.

1 November 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
NFNa Fan
Na Fan
JZJin Zhang
Jin Zhang
CCChuantao Cheng
Chuantao Cheng
XZXinwu Zhang
Xinwu Zhang
JFJie Feng
Jie Feng
RKRanran Kong
Ranran Kong

1 July 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
JZJin Zhang
Jin Zhang
RKRanran Kong
Ranran Kong
LSLiangzhang Sun
Liangzhang Sun

1 April 2017 in Oncology Reports
Verified
Journal Article
Open access
PDF file
RKRanran Kong
Ranran Kong
WLWei Liu
Wei Liu
YGYurui Guo
Yurui Guo
JFJie Feng
Jie Feng
CCChuantao Cheng
Chuantao Cheng
XHXijing He
Xijing He
MicroRNAs (miRNAs) play critical roles in the development and progression of various cancers, including non-small-cell lung cancer (NSCLC). Studies have suggested that miR-330-5p is involved in the progression of several cancers. However, the role of miR-330-5p in NSCLC remains unclear. We investigated the effect on and mechanism of miR-330-5p in the progression of NSCLC. We found that miR-330-5p was significantly downregulated in NSCLC tissues and cell lines as detected by real-time quantitative polymerase chain reaction (RT-qPCR). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), bromodeoxyuridine (BrdU), colony formation and cell cycle assays showed that overexpression of miR-330-5p markedly inhibited cell growth. Annexin V-FITC/PI and caspase-3 activity assays showed that overexpression of miR-330-5p significantly promoted cell apoptosis of NSCLC cells. Bioinformatics analysis and dual-luciferase reporter assays confirmed NIN/RPN12 binding protein 1 (NOB1) as a target gene of miR-330-5p. RT-qPCR and Western blot analysis showed that overexpression of miR-330-5p inhibited the expression of NOB1 as well as cyclin D1 and cyclin-dependent kinase 4 in NSCLC cells. Moreover, overexpression of NOB1 markedly reversed the miR‑330-5p-mediated inhibitory effect on NSCLC cell growth. Correlation analysis showed that miR‑330-5p expression was inversely correlated with NOB1 mRNA expression in NSCLC tissues. Taken together, our results indicate that miR-330-5p inhibits NSCLC cell growth through downregulation of NOB1 expression. Our study suggests that miR-330-5p may serve as a potential therapeutic target for the treatment of NSCLC.